A systems pharmacology approach has identified the capacity of baicalin to target 48 asthma-related genes such as IFNγ, IL4, IL5, IL10, IL13, and TNFα and signaling pathways, reinforcing its polypharmacological properties [2]. The gene discussed is IL4; the disease is asthma.